Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization

Addiction

Volumn 103, Issue 11, 2008, Pages 1801-1808

  Kranzler, Henry R ^a,e   Stephenson, Judith J ^b   Montejano, Leslie ^c   Wang, Shaohung ^c   Gastfriend, David R ^d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b HEALTHCORE INC   (United States)

^c Outcomes Research   (United States)

^d ALKERMES INC   (United States)

^e UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Adherence; Alcohol treatment; Alcohol related; Health care costs; Health care utilization; Naltrexone; Persistence; Pharmacotherapy

Indexed keywords

NALTREXONE;

ADULT; ALCOHOLISM; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG DETOXIFICATION; FEMALE; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PSYCHOTHERAPY;

ADULT; AGED; ALCOHOL DRINKING; ALCOHOLISM; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; HEALTH SERVICES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 54049104894     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2008.02345.x     Document Type: Article

References (29)

1. Grant B. F., Dawson D. A., Stinson F. S., Chou S. P., Dufour M. C., Pickering R. P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004 74 : 223 34.
2. Caetano R., Cunradi C. Alcohol dependence: a public health perspective. Addiction 1997 97 : 633 45.
3. Harwood H., Fountain D., Livermore G. The economic costs of alcohol and drug abuse in the United States 1992. Report prepared for the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Department of Health and Human Services. National Institute of Health Publication no. 98-4327. Rockville, MD: National Institutes of Health. 1998. Available at: http://www.nida.nih.gov/EconomicCosts/Index.html (accessed 6 July 2008).
4. Cohen E., Feinn R., Arias A., Kranzler H. R. Alcohol treatment utilization: findings from the National Epidemiologic Survey on alcohol and related conditions. Drug Alcohol Depend 2007 86 : 214 21.
5. Mojtabai R., Olfson M., Mechanic D. Perceived need and help-seeking in adults with mood, anxiety, or substance use disorders. Arch Gen Psychiatry 2002 59 : 77 84.
6. Rabinowitz J., Gross R., Feldman D. Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Soc Psychiatry Psychiatr Epidemiol 1999 34 : 141 6.
7. Regier D. A., Narrow W. E., Rae D. S., Manderscheid R. W., Locke B. Z., Goodwin F. K. The de facto US mental and addictive disorders service system. Epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993 50 : 85 94.
8. Wu L., Ringwalt C. L., Williams C. E. Use of substance abuse treatment services by persons with mental health and substance use problems. Psychiatr Serv 2003 54 : 363 9.
9. Johnson K. H., Bazargan M., Bing E. G. Alcohol consumption and compliance among inner-city minority patients with type 2 diabetes mellitus. Arch Fam Med 2000 9 : 964 70.
10. Bazargan-Hejazi S., Bazargan M., Hardin E., Bing E. G. Alcohol use and adherence to prescribed therapy among under-served Latino and African-American patients using emergency department services. Ethn Dis 2005 15 : 267 75.
11. Cook R. L., Sereika S. M., Hunt S. C., Woodward W. C., Erlen J. A., Conigliaro J. Problem drinking and medication adherence among persons with HIV infection. J Gen Intern Med 2001 16 : 83 8.
12. Cox W. M., Blount J. P., Crowe P. A., Singh S. P. Diabetic patients' alcohol use and quality of life: relationships with prescribed treatment compliance among older males. Alcohol Clin Exp Res 1996 20 : 327 31.
13. Weiss R. D. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004 99 : 1382 192.
14. Kranzler H. R. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol 2000 35 : 537 47.
15. Baros A. M., Latham P. K., Moak D. H., Voronin K., Anton R. F. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res 2007 31 : 596 603.
16. Pettinati H. M., Weiss R. D., Miller W. R., Donovan D. M., Ernst D. B., Rounsaville B. J. Medical management treatment manual: a clinical research guide for medically trained clinicians providing pharmacotherapy as part of the treatment for alcohol dependence. J Stud Alcohol Suppl 2005 15 : 170 8.
17. Del Boca F. K., Kranzler H. R., Brown J., Korner P. F. Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcohol Clin Exp Res 1996 20 : 1412 7.
18. Feinn R., Tennen H., Cramer J., Kranzler H. R. Measurement and prediction of medication compliance in problem drinkers. Alcohol Clin Exp Res 2003 27 : 1286 92.
19. Lafleur J., Thompson C. J., Joish V. N., Charland S. L., Oderda G. M., Brixner D. I. Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother 2006 40 : 1274 9.
20. Sajatovic M., Valenstein M., Blow F. C., Ganoczy D., Ignacio R. V. Treatment adherence with antipsychotic medications in bipolar disorder. Bipolar Disord 2006 8 : 232 41.
21. Siris E. S., Harris S. T., Rosen C. J., Barr C. E., Arvesen J. N., Abbott T. A. et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 81 : 1013 22.
22. Pettinati H. M., Volpicelli J. R., Pierce J. D. Jr., O'Brien, C. P. Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 2000 19 : 71 83.
23. Cramer J., Rosenheck R., Kirk G., Krol W., Krystal J. VA Naltrexone Study Group 42: medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003 6 : 566 73.
24. Starosta A. N., Leeman R. F., Volpicelli J. R. The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders. J Psychiatr Pract 2006 12 : 80 9.
25. O'Farrell T. J., Allen J. P., Litten R. Z. Disulfiram (Antabuse) contracts in treatment of alcoholism. NIDA Res Monogr 1995 150 : 65 91.
26. O'Malley S. S., Garbutt J. C., Gastfriend D. R., Dong Q., Kranzler H. R. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007 27 : 507 12.
27. Harris K. M., Devries A., Dimidjian K. Datapoints: trends in naltrexone use among members of a large private health plan. Psychiatr Serv 2004 55 : 221.
28. Hermos J. A., Young M. M., Gagnon D. R., Fiore L. D. Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population. Alcohol Clin Exp Res 2004 28 : 1229 35.
29. Mark T. L., Kranzler H. R., Song X. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 2003 71 : 219 28.